Small-Cap Healthcare Comparison: Oramed Pharmaceuticals vs. BeyondSpring
What happened
Oramed Pharmaceuticals Inc. and BeyondSpring were classified as small-cap healthcare companies. A comparison of the two firms showed that Oramed Pharmaceuticals has higher revenue and earnings than BeyondSpring. BeyondSpring is currently trading at a lower price-to-earnings ratio and has a significantly lower volatility compared to Oramed Pharmaceuticals.
From themarketsdaily.com
Why it matters
The comparison highlights differences in risk and valuation between the two small-cap firms. Oramed Pharmaceuticals has a beta of 1.31, indicating higher volatility, while BeyondSpring has a beta of -0.12. BeyondSpring also reports a higher percentage of institutional ownership at 40.3% compared to Oramed Pharmaceuticals' 12.7% of institutional ownership.
From themarketsdaily.com
Who's involved
- Oramed Pharmaceuticals Inc.Pharmaceutical company of Israel being analyzed
- Nadav KidronPresident and CEO of Oramed Pharmaceuticals Inc.
- FTSE RussellProvider of stock market indices related to Oramed Pharmaceuticals Inc.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Oramed Pharmaceuticals Inc.Speculative
Investment decisions in the small-cap healthcare sector might be influenced by the reported differences in valuation and risk.
Keep exploring
The entities involved
-
Oramed Pharmaceuticals Inc.
Pharmaceutical company of Israel
Nothing else this week.